ReviewEnvironmental research2021
Mucormycosis: An opportunistic pathogen during COVID-19.
Review in Environmental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Use of isavuconazole in mucormycosis: a systematic review.BMC infectious diseases · 2025Pooled it
- A systematic review on SARS-CoV-2-associated fungal coinfections.Journal of medical virology · 2022Pooled it
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Comparison of infectious complications following early versus late pulse steroid therapy in renal transplant recipients.World journal of nephrology · 2026Article
- Clinical Features and Predictive Risk Factors for Prognosis in Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis.The clinical respiratory journal · 2026Article
- Hospital Indoor Air as a Reservoir of Opportunistic Filamentous Fungi: Species Diversity and Antifungal Susceptibility.Current microbiology · 2026Article
- Transcriptomic and proteomic profiling of pulmonary mucormycosis reveals a failed activation of host immune response.Frontiers in immunology · 2026Article
- A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated MucormycosisEndocrine, metabolic & immune disorders drug targets · 2026Article
- Customised Patient-Specific Implants in Maxillofacial Reconstruction After Mucormycosis: A Case Series.Journal of maxillofacial and oral surgery · 2025Article
- Analysis of the clinical parameters and management aspects of rhino-maxillary mucormycosis, Part I: challenges in diagnosis.BMC oral health · 2025Article
- Mucormycosis and Hearing: A Hospital-Based Study.International archives of otorhinolaryngology · 2025Article
- Synthesis of Chitosan based nanoemulsions and their characterization and antifungal activity toward fungi causing mucormycosis.Scientific reports · 2025Article
- Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview.Infectious disorders drug targets · 2025Review
- Post Covid rhino - Orbital cerebral mucormycosis among Indian patients.Bioinformation · 2025Article
- Case Series of Post-COVID-19 Mucormycosis in Serbia/Rhino-Orbital-Cerebral Form: Surgical and Medical Treatment.Case reports in infectious diseases · 2025Article
- Review
- Impact of COVID-19 on mucormycosis presentation and laboratory values: A comparative analysis.PloS one · 2025Article
- The Black Fungus: A Rare Case of Pulmonary Mucormycosis.HCA healthcare journal of medicine · 2025Article
- Article
- Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) still remains on an upsurge trend. The second wave of this disease has led to panic in many countries, including India and some parts of the world suffering from the third wave. As there are no proper treatment options or remedies available for this deadly infection, supportive care equipment's such as oxygen cylinders, ventilators and heavy use of steroids play a vital role in the management of COVID-19. In the midst of this pandemic, the COVID-19 patients are acquiring secondary infections such as mucormycosis also known as black fungus disease. Mucormycosis is a serious, but rare opportunistic fungal infection that spreads rapidly, and hence prompt diagnosis and treatment are necessary to avoid high rate of mortality and morbidity rates. Mucormycosis is caused by the inhalation of its filamentous (hyphal form) fungi especially in the patients who are immunosuppressed. Recent studies have documented alarming number of COVID-19 patients with mucormycosis infection. Most of these patients had diabetes and were administered steroids for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and were consequently more prone to mucormycosis. Hence, the present review emphasizes mucormycosis and its related conditions, its mechanism in normal and COVID-19 affected individuals, influencing factors and challenges to overcome this black mold infection. Early identification and further investigation of this fungus will significantly reduce the severity of the disease and mortality rate in COVID-19 affected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.